Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-08-15

FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Actoplus Met, a fixed-dose combination of pioglitazone and metformin hydrochloride, submitted by Takeda Pharmace…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ACTOPLUS MET (pioglitazone and metformin hydrochloride)

Snippet

SUPPL AP for ACTOPLUS MET (PIOGLITAZONE AND METFORMIN HYDROCHLORIDE)